2008 to 2021 Saw Decrease in Delivery-Related Mortality
However, prevalence of any severe maternal morbidity increased during same time period
ADA: Reductions in Body Weight With Retatrutide for Obesity
Substantial reductions seen in body weight with retatrutide treatment for 48 weeks in phase 2 trial
Variation Seen in Distribution of Characteristics of COVID-19 During Pregnancy
Changes in distributions of mothers reported to have COVID-19 observed by maternal age, race and Hispanic origin, education level
Percutaneous Tibial Nerve Stimulation Beneficial for Overactive Bladder
Improvement seen in overactive bladder symptoms of urinary urgency, nocturia, incontinence, and frequency after 12 weeks of PTNS
Gestational Diabetes Tied to 11-Fold Higher Risk of Diabetes
Lower likelihood of subsequent glycemic control seen for Black, Hispanic women
Iron Deficiency Common Among Teens, Young Women
Prevalence varies by ferritin or hemoglobin thresholds used
ADA: Once-Weekly Icodec Superior for Reduction in HbA1c
Noninferior and superior reduction in HbA1c with one-weekly icodec versus once-daily degludec in insulin-naive type 2 diabetes patients
ADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D
Substantial and clinically meaningful reductions in body weight seen for adults with obesity and type 2 diabetes
ADA: Once-Daily Semaglutide Superior for Reduction in Body Weight
Superior and clinically meaningful reduction in body weight in adults with overweight, obesity without type 2 diabetes
ENDO: Women With Polycystic Ovary Syndrome Experience More Body Image Concerns
Authors say findings show need for body image screening in clinical practice
